Core Insights - Maikang Bio announced the completion of a multi-hundred million yuan D+ round financing on December 25, with investments from Chengdu Science and Technology Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Lanwan [1] Group 1: Financing Details - The funds raised will primarily support the market launch and commercialization of the recombinant shingles vaccine, the Phase III clinical research of the recombinant respiratory syncytial virus vaccine, and the preclinical development of multiple innovative vaccine pipelines and international collaborations [1] Group 2: Company Background - Established in 2016, Maikang Bio is a global biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines and novel adjuvants [1] - The company was founded by Dr. Chen Dexiang, a returnee PhD, and has been recognized as a national high-tech enterprise and a specialized and innovative enterprise in Sichuan Province, consistently listed in the GEI China (potential) unicorn enterprises list [1]

Group 1 - The "Good Hope Science Salon" held in Shanghai focused on the theme "The Path of Scientific Research: From Pathogen Basic Research to Infectious Disease Prevention and Control Applications," gathering over 130 experts from life sciences, technology enterprises, and investment institutions to discuss the latest research achievements and investment logic in the biopharmaceutical industry [1] - Gao Fu, an academician from the Chinese Academy of Sciences, emphasized the importance of understanding basic research to guide vaccine development, including the types of peptides or proteins to use [1] - Gao also highlighted the issue of "information viruses" and "information epidemics," which complicate public access to reliable information, stressing the need for effective science communication as a societal vaccine [1] Group 2 - Tang Chang, General Manager of Changzhou Longzang Biotechnology Co., Ltd., discussed the role of vaccine adjuvants in vaccine development, particularly their suitability for special populations such as children and the elderly, and the need for discovering better adjuvants [1] - Liu Kefang, Chairman of Beijing Xinzhi Biopharmaceutical Co., Ltd., noted the advantages of AI in integrating large datasets to aid in the design of immune responses, thereby supporting the development of broad-spectrum influenza vaccines [1]

Core Insights - The research on protein subunit vaccines has made significant progress, expanding the structure of the COVID-19 RBD subunit vaccine to octamers or hexamers, enhancing its broad-spectrum efficacy [1] - The COVID-19 pandemic has accelerated foundational research and industrialization in the fields of immunology and vaccines, emphasizing the importance of understanding basic research to shorten product development timelines [1] Group 1: Research and Development - Understanding the interaction mechanisms between viruses and cells is crucial for developing antiviral drugs and vaccines [3] - Research on how influenza viruses enter cells via sialic acid receptors can aid in creating drugs that block this process, while studying how viruses activate host immune responses can lead to more effective vaccines [3] - High-level breakthroughs in pathogen microbiology and immune response are driving innovative vaccine design and drug development [4] Group 2: Vaccine Effectiveness and Challenges - Vaccine effectiveness remains a significant issue in the vaccine industry, particularly with influenza vaccines due to the rapid mutation of respiratory viruses [4] - Various vaccine development strategies have been implemented since the outbreak of COVID-19, including inactivated vaccines, live attenuated vaccines, protein subunit vaccines, viral vector vaccines, mRNA vaccines, multivalent vaccines, and virus-like particle vaccines [4] Group 3: Public Health and Misinformation - Understanding virus transmission and pathogenic mechanisms is essential for formulating effective public health interventions, such as mask-wearing and social distancing [3] - The emergence of "infodemics" during biological outbreaks poses a challenge, with misinformation being as harmful as the viruses themselves, highlighting the need for scientific literacy as a societal vaccine [4]

Group 1 - The discussion focused on improving vaccine effectiveness and safety, highlighting the limitations of current mucosal immune mechanisms and basic immunology research in developing efficient and long-lasting vaccines [1][3] - The event, part of the "Cape of Good Hope Science Salon," gathered over 130 participants, including experts, entrepreneurs, and investment leaders, to explore the latest research and investment logic in pathogen research and infectious disease prevention [1][3] Group 2 - Gao Fu, a prominent immunologist and academician, emphasized that the viruses likely to cause future large-scale outbreaks are influenza and coronaviruses due to their respiratory nature and propensity for mutation [3] - He discussed various vaccine development strategies adopted in China post-COVID-19, including inactivated, live attenuated, protein subunit, viral vector, mRNA, multivalent, and virus-like particle vaccines, with a focus on protein subunit vaccines [4] - Recent breakthroughs in vaccine research include the development of the world's first recombinant subunit vaccine for COVID-19, with advancements in design strategies to enhance broad-spectrum efficacy [4]

Core Insights - The Scripps Research Institute has developed a novel vaccine strategy using engineered protein nanoparticles to present viral surface proteins, enhancing the immune system's ability to recognize and respond to filoviruses [1][2] - This new vaccine approach aims to provide broader protection against various deadly filoviruses, including Ebola and Marburg, which currently lack a universal vaccine [1] Group 1: Vaccine Development - The research team has focused on creating a universal vaccine design blueprint for major virus families, enabling rapid response to new virus outbreaks [2] - By employing structure-based rational design, the team has engineered stable and well-defined versions of viral glycoproteins, which are crucial for viral entry into host cells and are primary targets for the immune system [2] - The engineered nanoparticles have successfully induced a broad neutralizing antibody response in mice, laying the groundwork for a more comprehensive filovirus vaccine [2] Group 2: Future Directions - The team is expanding this strategy to other high-risk pathogens such as Lassa virus and Nipah virus, aiming to overcome the glycan shield that hinders immune system attacks on critical viral regions [2] - Despite advancements, the team acknowledges that stabilizing antigens only addresses 60% of the challenges, as dense glycan layers on many viruses remain a significant barrier [2]

Group 1 - The core focus of the news is the initiation of the Phase II clinical trial for the six-valent recombinant norovirus vaccine developed by YuanDa Life Sciences, which is the fastest progressing norovirus vaccine globally [1][2] - The vaccine utilizes virus-like particle (VLP) technology, covering six globally prevalent genotypes, theoretically addressing over 90% of circulating norovirus strains [1] - Norovirus is a major pathogen causing acute gastroenteritis, characterized by rapid mutation and high transmissibility, with a significant clinical demand for effective vaccines as no specific antiviral drugs or preventive vaccines are currently approved [1] Group 2 - The Phase II clinical trial launch meeting was hosted by experts from the Guangxi Disease Control Center, emphasizing collaboration and adherence to ethical and trial standards to ensure scientific and efficient progress [2] - According to Frost & Sullivan, the market for norovirus vaccines in China is projected to grow from 1.53 billion yuan to 22.93 billion yuan between 2026 and 2031, with a compound annual growth rate of 71.85% [2] - YuanDa Saiweixin is recognized as a leading innovative vaccine company in China, with a comprehensive international industrial layout and a robust pipeline of over ten innovative vaccine projects [3] Group 3 - The company has established four proprietary technology platforms, including recombinant protein VLP and new adjuvants, which form a solid foundation for research and development [3] - A vaccine production base that meets global high standards is under construction in Hangzhou, expected to support the commercialization of 8 to 10 new vaccines, with an anticipated annual output value exceeding 10 billion yuan [3]

Core Insights - The Butantan Institute in Brazil has developed the world's first single-dose dengue vaccine, which has been approved by the Brazilian Health Regulatory Agency for use in individuals aged 12 to 59 years [1] - The vaccine demonstrates a total efficacy of nearly 75% and over 90% efficacy in preventing severe cases, comparable to the currently used two-dose imported vaccines but with the advantage of requiring only one dose [1] - To expand production capacity, the Butantan Institute has partnered with a Chinese company, aiming to supply approximately 30 million doses by the second half of 2026 [1] - The vaccine is expected to be included in Brazil's national immunization program, although the specific timing and age groups for vaccination are yet to be determined by the government [1] - The Brazilian Ministry of Health reported over 6.5 million suspected dengue cases and more than 6,300 deaths in 2024, with over 1.63 million suspected cases still reported as of November 22, 2025 [1] Company and Industry Summary - The Butantan Institute's vaccine represents a significant breakthrough in Brazil's scientific and health sectors, addressing a long-standing public health issue with an effective single-dose solution [1] - The collaboration with a Chinese company for vaccine production indicates a strategic move to enhance manufacturing capabilities and meet the anticipated demand for dengue vaccination in Brazil [1] - The ongoing dengue outbreak in Brazil highlights the urgent need for effective vaccination solutions, as evidenced by the high number of suspected cases and fatalities reported in recent years [1]

每经记者｜陈星 实习生 范芊芊 每经编辑｜文多 4月10日，2021全国疫苗与健康大会在成都召开。国家卫生健康委医药卫生科技发展研究中心主任、国 务院联防联控机制科研攻关组疫苗研发工作组组长郑忠伟参与了"由新冠疫苗看中国疫苗创新"为主题的 圆桌访谈。他表示，对于中国疫苗研发，在坚定自信的同时，也要了解不足。 "从此次新冠疫苗研发来看，我们所有的中国人既要有中国自信，也要有中国冷静。"他说。 封面图片来源：摄图网 他指出，在生物医药领域，我国有一些国家优势，包括体制、组织、文化优势；而不足则体现在基础研 究、载体平台、组织研发等方面，尤其在国际临床项目上与国外差距明显。 那么国际临床项目上的差距如何补足？他说，"十四五"期间，国家大概要投入40亿元左右用于推进病原 学和免疫技术体系方面的研发项目。其次，重大传染病专项培养技术也会在"十四五"期间尽早投入。另 外，目前一些疫苗方面的突破得益于企业的储备。 ...

Core Viewpoint - The company, Liaoning Chengda, has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not provide further large cash injections, focusing instead on attracting strategic investors and shifting its focus towards core industries like biomedicine [1] Group 1: Company Strategy and Management - The new management team, elected in February, is actively optimizing the financing structure and controlling funding costs to ensure stable operations across all business segments [2] - The company has issued short-term financing bonds with decreasing interest rates, indicating a successful reduction in financing costs [2] - The management aims to enhance the company's core competitiveness and sustainable development through non-public issuance of exchangeable bonds [3] Group 2: Financial Performance and Investments - The company has seen significant growth in investment income from its holdings in Guangfa Securities and China Insurance, with year-on-year increases of 53.19% and 143.94%, respectively [4] - The capital market has rebounded, contributing to the increase in asset values and overall financial performance [4] Group 3: Focus on Biomedicine - The company has partnered with the Chinese Academy of Sciences to establish an AI-based vaccine research laboratory, aiming to enhance innovation in vaccine development [6] - Ongoing collaborations with the Chinese Academy of Microbiology focus on infectious disease prevention, with several vaccine candidates in various stages of clinical trials [7] - The company is expanding its vision beyond human vaccines to explore early-stage biopharmaceutical technologies and potential mergers and acquisitions to create a second growth curve [7]

本轮融资由领航新界资本领投。本轮所募资金将主要用于加速公司化学合成QS-21等佐剂原料的GMP生 产基地建设，推动在全球范围内的商业化进程，并进一步拓展公司在新型佐剂领域的研发管线。 11月21日，重庆百达信生物技术有限公司（以下简称"百达信生物"或"公司"）宣布已成功完成超过3000 万元人民币的Pre-A轮融资。 ...